How many mCRPC patients do you see per month, on average?

How would you best describe your practice?

• Academic
• Community
• Private
• Other

How would you describe the size of your practice?

• Large
• Small
• Other

Which of the following describes your practice?

• Outpatient
• Hospital
• Other

How does your PSMA-PET imaging volume compare with 6 months ago?

• Increased volume
• About the same
• Decreased volume

How do you anticipate your PSMA-PET imaging volumes to change over the next 6 months?

• Volume will increase
• Volume will be about the same
• Volume will decrease

How are you currently distributing your usage among the following PSMA-PET imaging agents?

• Pylarify
• Illuccix
• Posluma
• Locametz
• Other

Please offer insights into the distribution usage in your previous response and explain what factors influenced your choice of the preferred agent or agents.

Do you currently use or plan to use PSMA-PET imaging off-label (for disease monitoring or earlier stage patients)?

How do you expect your usage among the following PSMA-PET imaging agents to be in 1 year?

• Pylarify
• Illuccix
• Posluma
• Locametz
• Other

Please offer insights into the distribution usage in your previous response and explain what factors influenced your choice of the preferred agent or agents.

How frequently are PSMA PET scans repeated (in terms of months) for patients undergoing PSMA-directed therapy as part of their treatment follow-up, excluding the initial diagnostic scan?

How will expiration of pass through payment affect your center's use of Pylarify?

What do you see as the main difference between Pylarify and Posluma (if any)?

How many patients have you started on Pluvicto (Novartis Lu-PSMA-617) in the commercial setting (excluding patients treated on clinical trials)?

And given the recently released PSMAFore results (Lu-PSMA-617) and SPLASH topline results (PNT2002) ,to what extent do you expect the number of PSMA treated patients to change in the next year? Please indicate a positive or negative percentage %.

If Pluvicto (Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T) were both approved for 2L mCRPC with comparable outcomes, how do you expect to distribute your usage between these two products? Please indicate 0-100 for each, must sum to 100.

• Pluvicto (Lu-PSMA-617)
• PNT-2002 (Lu-PSMA-I&T)

Given recently released results from both Pluvicto (Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T), how do you expect to distribute your usage between these two products?